Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Operating Margin · Q3 FY2026 · quarter ended Sep 2026
Operating margin narrows to 20.7%
Operating margin was 20.7% in Q3 FY2026, down 17.8 pp from a year earlier. On a trailing-twelve-month basis it was 33.9%, down 0.2 pp year over year. Over 3 fiscal years it narrowed by 8.8 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 21 analysts of 52.6% for the fiscal year ending Dec 2026, up from 39.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 20.7%-16.7 pp QoQ
- Last fiscal yearDec 2025
- 39.4%+41.5 pp YoY
- LTMSep 2026
- 33.9%-0.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 39.4%
- Year-over-year change
- +41.5pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.4% | +41.5pp |
| FY2024 | 2024-12-31 | -2.1% | -40.9pp |
| FY2023 | 2023-12-31 | 38.8% | -9.4pp |
| FY2022 | 2022-12-31 | 48.2% | +11.5pp |
| FY2021 | 2021-12-31 | 36.7% | — |
Operating Margin vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Sep 2026 operating margin of 33.9% is the highest of the 11 companies compared; the peer median is -67.6%.
- Its year-over-year change of -0.2 pp is the 7th highest of 11, against a peer median of +3.2 pp.
- Over three fiscal years its change of -8.8 pp compares with a peer median of +106.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 33.9% | -0.2 pp | -8.8 pp | |
| LTM Jun 2026 | 20.8% | +28.1 pp | +89.2 pp | |
| LTM Jun 2026 | 11.5% | -29.2 pp | +113.5 pp | |
| LTM Mar 2026 | -1.9% | +3.4 pp | +27.5 pp | |
| LTM Sep 2026 | -8.0% | -27.9 pp | +8.9 pp | |
| LTM Sep 2026 | -58.9% | -30.2 pp | +29.4 pp | |
| LTM Jun 2026 | -76.2% | +202.2 pp | +546.3 pp | |
| LTM Mar 2026 | -83.9% | +3.0 pp | +99.1 pp | |
| LTM Jun 2026 | -242.3% | +497.7 pp | +281.0 pp | |
| LTM Mar 2026 | -636.6% | +550.8 pp | +227.4 pp | |
| LTM Sep 2026 | -2104.9% | -834.8 pp | +138203.3 pp | |
| Peer median (excluding VRTX) | -67.6% | +3.2 pp | +106.3 pp | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57B | 8.93B | 9.87B | 11.02B | 12.07B |
| Cost of Revenue | 904.2M | 1.08B | 1.26B | 1.53B | 1.81B |
| Gross Profit | 6.67B | 7.85B | 8.61B | 9.49B | 10.27B |
| Gross Margin | 88.1% | 87.9% | 87.2% | 86.1% | 85.0% |
| Research & Development | 3.05B | 2.66B | 3.16B | 3.63B | 3.75B |
| Selling, General & Admin | 840.1M | 944.7M | 1.14B | 1.46B | 1.75B |
| Operating Expenses | 3.89B | 3.54B | 4.78B | 9.72B | 5.51B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| EBITDA | 2.92B | 4.44B | 4.61B | 486.3M | 4.87B |
| EBITDA Margin | 38.5% | 49.7% | 46.7% | 4.4% | 40.3% |
| Operating Income | 2.78B | 4.31B | 3.83B | (232.9M) | 4.76B |
| Operating Margin | 36.7% | 48.2% | 38.8% | -2.1% | 39.4% |
| Interest Income | 4.9M | 144.6M | 614.7M | 598.1M | 490.9M |
| Interest Expense | 61.5M | 54.8M | 44.1M | 30.6M | 13.3M |
| Other Income / Expenses | (51.7M) | (75M) | 547.8M | 481.4M | (117.5M) |
| Income Before Tax | 2.73B | 4.23B | 4.38B | 248.5M | 4.64B |
| Pre-Tax Margin | 36.0% | 47.4% | 44.4% | 2.3% | 38.5% |
| Income Tax Expense | 388.3M | 910.4M | 760.2M | 784.1M | 690M |
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Net Margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.7% |
| EPS (Basic) | 9.09 | 12.97 | 14.05 | (2.08) | 15.46 |
| EPS (Diluted) | 9.01 | 12.82 | 13.89 | (2.08) | 15.32 |
| Weighted Avg Shares | 257.7M | 256.1M | 257.7M | 257.5M | 255.7M |
| Weighted Avg Shares (Diluted) | 259.9M | 259.1M | 260.5M | 257.9M | 258M |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.